Literature DB >> 3479550

Enantiomers of thiorphan and acetorphan: correlation between enkephalinase inhibition, protection of endogenous enkephalins and behavioral effects.

B Giros1, C Gros, J C Schwartz, D Danvy, J C Plaquevent, L Duhamel, P Duhamel, A Vlaiculescu, J Costentin, J M Lecomte.   

Abstract

The relationships between various properties of inhibitors of enkephalinase (membrane metalloendopeptidase, EC 3.4.24.11) i.e., enzyme inhibition, protection of endogenous enkephalins, antinociceptive activity and stimulation of locomotor activity was investigated by comparing the relative potencies of the two enantiomers of Thiorphan and acetorphan, its parenterally active prodrug. In vitro (R)- and (S)-Thiorphan were almost equipotent in inhibiting enkephalinase activity (Ki, 1.7 and 2.2 nM, respectively) or thermolysin activity (Ki, 13 and 6 microM, respectively) whereas the (R)-isomer was 44-fold less potent than the (S)-isomer on ACE activity (Ki 4800 and 110 nM, respectively). When tested on slices of rat globus pallidus in the presence of bestatin, to block the aminopeptidase pathway of enkephalin degradation, both Thiorphan enantiomers ensured a complete protection of endogenous (Met5)enkephalin released by depolarization and a suppression of the increase in the extracellular levels of Tyr-Gly-Gly, a characteristic enkephalin metabolite. These two effects occurred at EC50 values of the two enantiomers (10 nM in both cases), consistent with the idea that they were due to enkephalinase inhibition. After i.v. administration of the acetorphan enantiomers to mice, the enkephalinase activity of a rapidly prepared striatal membrane fraction was reduced in a dose-dependent manner with similar "ex vivo" ED50 values (1.0 and 0.3 mg/kg for the (R)- and (S)-isomer, respectively). In contrast the ACE activity of the same preparation was reduced in a significant manner only by (S)-acetorphan (ED50 value of 11 mg/kg).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3479550

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Importance of delta opioid receptors in maintaining high alcohol drinking.

Authors:  J C Froehlich; M Zweifel; J Harts; L Lumeng; T K Li
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.

Authors:  C Gros; N Noël; A Souque; J C Schwartz; D Danvy; J C Plaquevent; L Duhamel; P Duhamel; J M Lecomte; J Bralet
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

3.  Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.

Authors:  C Gros; A Souque; J C Schwartz; J Duchier; A Cournot; P Baumer; J M Lecomte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

4.  Purification, cDNA cloning, functional expression, and characterization of a 26-kDa endogenous mammalian carboxypeptidase inhibitor.

Authors:  E Normant; M P Martres; J C Schwartz; C Gros
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

5.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

Review 6.  A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Authors:  Makoto Katori; Masataka Majima
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-07

7.  Pharmacologic Comparison of Clinical Neutral Endopeptidase Inhibitors in a Rat Model of Acute Secretory Diarrhea.

Authors:  David W Griggs; Michael J Prinsen; Jonathan Oliva; Mary A Campbell; Stacy D Arnett; Deena Tajfirouz; Peter G Ruminski; Ying Yu; Brian R Bond; Yuhua Ji; Georg Neckermann; Robert K M Choy; Eugenio de Hostos; Marvin J Meyers
Journal:  J Pharmacol Exp Ther       Date:  2016-02-23       Impact factor: 4.030

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.